Aditxt, Inc. SEC 10-Q Report

Aditxt, Inc., a biotechnology company specializing in immune monitoring and reprogramming technologies, has released its Form 10-Q report for the third quarter. The report provides a detailed overview of the company's financial performance and operational activities, reflecting both challenges and strategic initiatives aimed at future growth.

Financial Highlights

• Sales: $1,018, reflecting a significant decrease from $79,680 in the prior year period, indicating a substantial drop in revenue generation.
• Gross Loss: $284, compared to $13,881 in the previous year, showing a reduction in gross loss despite lower sales.
• Net Loss from Operations: $(5,608,115), a decrease from $(11,535,646) in the prior year, suggesting improved operational efficiency.
• Net Loss: $(5,952,465), compared to $(14,868,694) in the previous year, indicating a reduction in overall losses.
• Net Loss Per Share, Basic and Diluted: $(8.12), a significant improvement from $(91,439.43) in the prior year, reflecting the impact of reverse stock splits and changes in share count.

Business Highlights

• Revenue Segments: The company reported revenue from its AditxtScore™ services, which involve the analysis of specimens in its CLIA laboratory and the generation of results delivered to customers.
• Geographical Performance: The company operates a CLIA-certified, CAP-accredited, high-complexity immune monitoring center in Richmond, Virginia, and maintains its corporate headquarters in Mountain View, California.
• Future Outlook: The company is actively pursuing numerous capital-raising transactions to meet existing capital needs and longer-term objectives. It is also focused on strategic acquisitions and alliances to strengthen its business operations.

SEC Filing: Aditxt, Inc. [ ADTX ] - 10-Q - May. 15, 2025